TY - JOUR T1 - For patients with chronic asthma not controlled with inhaled corticosteroids alone, long-acting β-agonists are associated with fewer exacerbations than leukotriene receptor agonists JF - Evidence Based Medicine JO - Evid Based Med SP - 174 LP - 174 DO - 10.1136/eb-2014-110032 VL - 19 IS - 5 AU - Gene Colice Y1 - 2014/10/01 UR - http://ebm.bmj.com/content/19/5/174.abstract N2 - Commentary on: Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2014;1:CD003137. Outside of a clinical trial setting, most patients with asthma have poorly controlled asthma.1 ,2 Inadequate control of asthma in the community may reflect poor adherence to controller medications; however, the GOAL trial demonstrated that low-to-medium dose inhaled corticosteroids (ICS) were unsuccessful in achieving asthma control in a large proportion of patients with asthma, even with close supervision of care.3 Asthma management guidelines recommend an additional controller medication when asthma control is not achieved with ICS.4 Although the preferred second-choice controller medication is a long-acting inhaled β2-agonist (LABA), safety concerns regarding LABA use lead many clinicians to add a leukotriene receptor antagonist (LTRA) in its place. This review aimed to compare the efficacy and safety profiles of combinations … ER -